Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18623827 | 0.84 | GRM5 (0.34) | GRM5 | |
| SCHEMBL18623803 | 0.83 | GRM5 (0.32) | GRM5 | |
| SCHEMBL18623819 | 0.83 | DYRK1A (0.42) | GRM5TGFBR1 | |
| SCHEMBL18623831 | 0.82 | GRM5 (0.34) | GRM5NPC1RAB9AALDH1A1 | |
| SCHEMBL17080366 | 0.81 | ABL1 (0.34) | GRM5TGFBR1EGLN2 | |
| SCHEMBL18623828 | 0.81 | GRM5 (0.32) | GRM5 | |
| SCHEMBL18623823 | 0.80 | GRM5 (0.45) | GRM5 | |
| SCHEMBL18623804 | 0.80 | TGFBR1 (0.35) | TGFBR1 | |
| SCHEMBL18623808 | 0.79 | NPC1 (0.47) | GRM5TGFBR1NPC1RAB9AALDH1A1 | |
| SCHEMBL18623825 | 0.79 | GRM5 (0.30) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106103444-B | Microbicidal heterobicyclic derivatives | 先正达参股股份有限公司 | 2019-03-12 | — | — | CN | disclosed |
| US-9896454-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9896454-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9896454-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| EP-3114127-B1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-20170073346-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20170073346-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20170073346-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| EP-3114127-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | Syngenta Participations AG (CH) | 2017-01-11 | — | — | EP | disclosed |
| CN-106103444-A | Microbicidal heterobicyclic derivatives | 先正达参股股份有限公司 | 2016-11-09 | — | — | CN | disclosed |
| WO-2015132133-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073346-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | MSR1, C1R, C3AR1 | GRM5 1798/4885TGFBR1 714/4885NPC1 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.